AR067444A1 - Derivados de pirazinona, procesos de obtencion y composiciones farmaceuticas - Google Patents
Derivados de pirazinona, procesos de obtencion y composiciones farmaceuticasInfo
- Publication number
- AR067444A1 AR067444A1 ARP080102812A ARP080102812A AR067444A1 AR 067444 A1 AR067444 A1 AR 067444A1 AR P080102812 A ARP080102812 A AR P080102812A AR P080102812 A ARP080102812 A AR P080102812A AR 067444 A1 AR067444 A1 AR 067444A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally
- alkoxy
- aryl
- substituted
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 43
- 125000003118 aryl group Chemical group 0.000 abstract 25
- 125000005843 halogen group Chemical group 0.000 abstract 18
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 17
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 17
- 125000004429 atom Chemical group 0.000 abstract 12
- 125000001072 heteroaryl group Chemical group 0.000 abstract 11
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 8
- 229910052799 carbon Inorganic materials 0.000 abstract 7
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 6
- 125000001424 substituent group Chemical group 0.000 abstract 6
- -1 O-aryl Chemical group 0.000 abstract 5
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 150000001721 carbon Chemical group 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 4
- 229910052717 sulfur Inorganic materials 0.000 abstract 4
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 2
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94641507P | 2007-06-27 | 2007-06-27 | |
| US97816707P | 2007-10-08 | 2007-10-08 | |
| US2944408P | 2008-02-18 | 2008-02-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR067444A1 true AR067444A1 (es) | 2009-10-14 |
Family
ID=39745171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080102812A AR067444A1 (es) | 2007-06-27 | 2008-06-27 | Derivados de pirazinona, procesos de obtencion y composiciones farmaceuticas |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US8163905B2 (enExample) |
| EP (1) | EP2170848B1 (enExample) |
| JP (2) | JP5140154B2 (enExample) |
| KR (1) | KR101541203B1 (enExample) |
| CN (1) | CN101842361B (enExample) |
| AR (1) | AR067444A1 (enExample) |
| AU (1) | AU2008269516B2 (enExample) |
| BR (1) | BRPI0813244B8 (enExample) |
| CA (1) | CA2691215C (enExample) |
| CL (1) | CL2008001898A1 (enExample) |
| CO (1) | CO6251251A2 (enExample) |
| CY (1) | CY1115836T1 (enExample) |
| DK (1) | DK2170848T3 (enExample) |
| EC (1) | ECSP109903A (enExample) |
| ES (1) | ES2525716T3 (enExample) |
| HR (1) | HRP20141174T1 (enExample) |
| IL (1) | IL202826A (enExample) |
| MY (1) | MY153258A (enExample) |
| NZ (1) | NZ581942A (enExample) |
| PE (1) | PE20090547A1 (enExample) |
| PL (1) | PL2170848T3 (enExample) |
| PT (1) | PT2170848E (enExample) |
| RS (1) | RS53682B1 (enExample) |
| RU (1) | RU2479580C2 (enExample) |
| SG (1) | SG182958A1 (enExample) |
| SI (1) | SI2170848T1 (enExample) |
| TW (1) | TWI448288B (enExample) |
| UA (1) | UA98961C2 (enExample) |
| UY (1) | UY31183A1 (enExample) |
| WO (1) | WO2009001132A1 (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2479580C2 (ru) | 2007-06-27 | 2013-04-20 | Астразенека Аб | Производные пиразинона и их применение для лечения легочных заболеваний |
| US20090011994A1 (en) | 2007-07-06 | 2009-01-08 | Bristol-Myers Squibb Company | Non-basic melanin concentrating hormone receptor-1 antagonists and methods |
| AR073711A1 (es) | 2008-10-01 | 2010-11-24 | Astrazeneca Ab | Derivados de isoquinolina |
| WO2010043721A1 (en) | 2008-10-17 | 2010-04-22 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
| US8969350B2 (en) * | 2008-12-18 | 2015-03-03 | Astrazeneca Ab | Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient |
| US8993808B2 (en) | 2009-01-21 | 2015-03-31 | Oryzon Genomics, S.A. | Phenylcyclopropylamine derivatives and their medical use |
| TW201036957A (en) | 2009-02-20 | 2010-10-16 | Astrazeneca Ab | Novel salt 628 |
| GB0913345D0 (en) | 2009-07-31 | 2009-09-16 | Astrazeneca Ab | New combination 802 |
| US8859555B2 (en) | 2009-09-25 | 2014-10-14 | Oryzon Genomics S.A. | Lysine Specific Demethylase-1 inhibitors and their use |
| EP2486002B1 (en) | 2009-10-09 | 2019-03-27 | Oryzon Genomics, S.A. | Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use |
| WO2011061527A1 (en) | 2009-11-17 | 2011-05-26 | Astrazeneca Ab | Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases |
| US9138441B2 (en) | 2009-12-31 | 2015-09-22 | Ira Milton Trachtman | Compositions and method for treatment and prophylaxis of inflammatory bowel disease |
| WO2011106573A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae |
| US9616058B2 (en) | 2010-02-24 | 2017-04-11 | Oryzon Genomics, S.A. | Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use |
| MX2012012111A (es) | 2010-04-19 | 2013-05-30 | Oryzon Genomics Sa | Inhibidores de demetilasa-1 especifica de lisina y su uso. |
| WO2012013727A1 (en) | 2010-07-29 | 2012-02-02 | Oryzon Genomics S.A. | Cyclopropylamine derivatives useful as lsd1 inhibitors |
| SI2598482T1 (sl) | 2010-07-29 | 2018-09-28 | Oryzon Genomics, S.A. | Inhibitorji demetilaze lsd1 na osnovi arilciklopropilamina in njihova medicinska uporaba |
| TWI535712B (zh) * | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | 化合物 |
| GB201016912D0 (en) | 2010-10-07 | 2010-11-24 | Astrazeneca Ab | Novel combination |
| WO2012045883A1 (en) | 2010-10-08 | 2012-04-12 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
| WO2012072713A2 (en) | 2010-11-30 | 2012-06-07 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae |
| GB201021992D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | Compound |
| GB201021979D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | New compound |
| WO2012107498A1 (en) | 2011-02-08 | 2012-08-16 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
| EP2741741A2 (en) * | 2011-05-19 | 2014-06-18 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for inflammatory diseases or conditions |
| CN107266345B (zh) | 2011-10-20 | 2021-08-17 | 奥瑞泽恩基因组学股份有限公司 | 作为lsd1抑制剂的(杂)芳基环丙胺化合物 |
| RS58475B1 (sr) | 2011-10-20 | 2019-04-30 | Oryzon Genomics Sa | Jedinjenja (hetero)aril ciklopropilamina kao lsd1 inhibitori |
| BR112014025201A2 (pt) | 2012-04-10 | 2017-07-11 | Sumitomo Dainippon Pharma Co Ltd | derivado de indazol 1-substituído |
| ES2716008T3 (es) | 2012-07-18 | 2019-06-07 | Sunshine Lake Pharma Co Ltd | Derivados heterocíclicos nitrogenados y su aplicación en fármacos |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| US20140302819A1 (en) * | 2013-04-05 | 2014-10-09 | Microsoft Corporation | Techniques for selecting a proximity card of a mobile device for access |
| AU2014306149B2 (en) | 2013-08-06 | 2019-09-19 | Imago Biosciences Inc. | KDM1A inhibitors for the treatment of disease |
| MX376632B (es) * | 2014-06-27 | 2025-03-07 | Celgene Quanticel Res Inc | Inhibidores de demetilasa-1 especifica de lisina. |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| KR102626978B1 (ko) | 2015-02-12 | 2024-01-18 | 이마고 바이오사이언시즈 인코포레이티드 | 질환 치료를 위한 kdm1a 저해제 |
| JP6691972B2 (ja) * | 2016-03-24 | 2020-05-13 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | 結晶形態 |
| CN108884070B (zh) * | 2016-04-07 | 2021-07-02 | 葛兰素史克知识产权第二有限公司 | 作为溴结构域抑制剂的吡啶基衍生物 |
| US11390590B2 (en) | 2016-08-16 | 2022-07-19 | Imago Biosciences, Inc. | Methods and processes for the preparation of KDM1A inhibitors |
| EP3515446B1 (en) | 2016-09-19 | 2023-12-20 | Novartis AG | Therapeutic combinations comprising a raf inhibitor and a erk inhibitor |
| EP3529242A1 (en) * | 2016-10-19 | 2019-08-28 | Constellation Pharmaceuticals, Inc. | Synthesis of inhibitors of ezh2 |
| CN106674029B (zh) * | 2016-12-23 | 2018-08-21 | 四川久凌制药科技有限公司 | 一种他喷他多中间体的制备方法 |
| US11266653B2 (en) | 2017-05-02 | 2022-03-08 | Novartis Ag | Combination therapy |
| KR102684364B1 (ko) | 2018-05-11 | 2024-07-11 | 이마고 바이오사이언시즈 인코포레이티드 | 질환의 치료를 위한 kdm1a 저해제 |
| KR102865950B1 (ko) * | 2019-03-22 | 2025-09-30 | 사니오나 에이/에스 | 신규의 칼륨 채널 억제제 |
| ES3025633T3 (en) | 2019-05-13 | 2025-06-09 | Novartis Ag | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer |
| DK4122926T3 (da) * | 2021-04-14 | 2025-06-30 | Shionogi & Co | Triazinderivater med virusreplikationsinhiberende aktivitet og farmaceutisk sammensætning, der omfatter disse |
| CN113999129B (zh) * | 2021-11-23 | 2023-09-01 | 长沙普济生物科技股份有限公司 | 一种含酚羟基氨基酸表面活性剂的合成方法 |
| WO2025122555A1 (en) * | 2023-12-05 | 2025-06-12 | Valo Health, Inc. | S1p 1 receptor agonists and uses thereof |
| CN119350255B (zh) * | 2024-10-21 | 2025-12-09 | 海南大学 | 一种酮衍生物及其合成方法和用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4199309B2 (ja) * | 1996-09-06 | 2008-12-17 | 日本化薬株式会社 | 新規アセトアミド誘導体およびプロテアーゼ阻害 |
| TWI328007B (en) | 2002-01-16 | 2010-08-01 | Astrazeneca Ab | Novel compounds |
| MXPA04008822A (es) | 2002-03-14 | 2004-11-26 | Bayer Healthcare Ag | Aroilpiridinonas monociclicas. |
| MXPA05000784A (es) | 2002-07-19 | 2005-06-17 | Biovitrum Ab | Derivados de piperazinil-pirazinona novedosos para el tratamiento de los trastornos relacionados con el receptor 5-ht2a. |
| MXPA06003615A (es) | 2003-09-30 | 2006-06-05 | Amgen Inc | Ligandos del receptor vanilloide y su uso en tratamientos. |
| WO2005035527A1 (en) * | 2003-10-14 | 2005-04-21 | Pharmacia Corporation | Substituted pyrazinone compounds for the treatment of inflammation |
| NZ545694A (en) * | 2003-12-03 | 2010-04-30 | Ym Bioscience Australia Pty Lt | Azole-based kinase inhibitors |
| GB0402812D0 (en) * | 2004-02-09 | 2004-03-10 | Tanabe Seiyaku Co | Novel compounds |
| CA2572119A1 (en) | 2004-06-29 | 2006-01-12 | Warner-Lambert Company Llc | Combination therapies utilizing benzamide inhibitors of the p2x7 receptor |
| JP4496092B2 (ja) | 2005-01-12 | 2010-07-07 | 信越化学工業株式会社 | 光ファイバ母材の製造方法及び装置 |
| ES2412007T3 (es) | 2005-12-21 | 2013-07-09 | Janssen Pharmaceutica, N.V. | Derivados de pirazinona sustituida novedosos para uso en enfermedades mediadas por MCH-1 |
| GB0608837D0 (en) | 2006-05-04 | 2006-06-14 | Chroma Therapeutics Ltd | Inhibitors of MAP kinase |
| NZ573348A (en) | 2006-05-04 | 2012-01-12 | Chroma Therapeutics Ltd | p38 MAP KINASE INHIBITORS |
| TW200808771A (en) * | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds II |
| JP2009537602A (ja) * | 2006-05-22 | 2009-10-29 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 薬剤として用いるための置換ピラジノン誘導体 |
| TW200924754A (en) * | 2006-06-21 | 2009-06-16 | Du Pont | Pyrazinones as cellular proliferation inhibitors |
| EP2034993A2 (en) * | 2006-06-21 | 2009-03-18 | E.I. Du Pont De Nemours And Company | Pyrazinones as cellular proliferation inhibitors |
| RU2479580C2 (ru) * | 2007-06-27 | 2013-04-20 | Астразенека Аб | Производные пиразинона и их применение для лечения легочных заболеваний |
-
2008
- 2008-06-25 RU RU2009148673/04A patent/RU2479580C2/ru active
- 2008-06-25 RS RS20140664A patent/RS53682B1/sr unknown
- 2008-06-25 CA CA2691215A patent/CA2691215C/en active Active
- 2008-06-25 AU AU2008269516A patent/AU2008269516B2/en not_active Ceased
- 2008-06-25 SG SG2012047502A patent/SG182958A1/en unknown
- 2008-06-25 MY MYPI20095582A patent/MY153258A/en unknown
- 2008-06-25 JP JP2010514138A patent/JP5140154B2/ja not_active Expired - Fee Related
- 2008-06-25 DK DK08776162.3T patent/DK2170848T3/en active
- 2008-06-25 NZ NZ581942A patent/NZ581942A/en unknown
- 2008-06-25 HR HRP20141174AT patent/HRP20141174T1/hr unknown
- 2008-06-25 PT PT87761623T patent/PT2170848E/pt unknown
- 2008-06-25 KR KR1020107001749A patent/KR101541203B1/ko not_active Expired - Fee Related
- 2008-06-25 PL PL08776162T patent/PL2170848T3/pl unknown
- 2008-06-25 BR BRPI0813244A patent/BRPI0813244B8/pt not_active IP Right Cessation
- 2008-06-25 ES ES08776162.3T patent/ES2525716T3/es active Active
- 2008-06-25 EP EP08776162.3A patent/EP2170848B1/en active Active
- 2008-06-25 CN CN2008801051412A patent/CN101842361B/zh not_active Expired - Fee Related
- 2008-06-25 WO PCT/GB2008/050491 patent/WO2009001132A1/en not_active Ceased
- 2008-06-25 SI SI200831338T patent/SI2170848T1/sl unknown
- 2008-06-25 UA UAA200913136A patent/UA98961C2/uk unknown
- 2008-06-26 TW TW097123868A patent/TWI448288B/zh not_active IP Right Cessation
- 2008-06-26 UY UY31183A patent/UY31183A1/es not_active Application Discontinuation
- 2008-06-26 US US12/147,132 patent/US8163905B2/en not_active Expired - Fee Related
- 2008-06-26 CL CL2008001898A patent/CL2008001898A1/es unknown
- 2008-06-27 AR ARP080102812A patent/AR067444A1/es active IP Right Grant
- 2008-06-27 PE PE2008001103A patent/PE20090547A1/es active IP Right Grant
-
2009
- 2009-12-17 IL IL202826A patent/IL202826A/en active IP Right Grant
- 2009-12-18 CO CO09145294A patent/CO6251251A2/es active IP Right Grant
-
2010
- 2010-01-27 EC EC2010009903A patent/ECSP109903A/es unknown
-
2012
- 2012-03-06 US US13/412,907 patent/US8299246B2/en not_active Expired - Fee Related
- 2012-09-14 US US13/616,179 patent/US8889692B2/en active Active
- 2012-09-25 JP JP2012211413A patent/JP5539473B2/ja not_active Expired - Fee Related
-
2014
- 2014-11-17 US US14/543,194 patent/US20150073136A1/en not_active Abandoned
- 2014-12-17 CY CY20141101059T patent/CY1115836T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR084152A1 (es) | Compuestos de triazolopirimidina como inhibidores de pde10a, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades del snc | |
| AR040514A1 (es) | Heterociclos diarilicos sustituidos, procedimiento para la preparacion de medicamentos y la utilizacion de los compuestos para tal fin | |
| CO6251251A2 (es) | Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares | |
| AR075402A1 (es) | Derivados heterociclicos oxigenados y/o nitrogenados de tetrahidronaftaleno, medicamentos que los contienen y uso de los mismos en el tratamiento de trastornos metabolicos, tales como obesidad,entre otros. | |
| PE20160751A1 (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
| MX343264B (es) | Ciertas amino-piridazinas, composiciones de las mismas y metodos de uso de los mismos. | |
| AR059458A1 (es) | Arildihidroisoquinolinonas sustituidas con azaciclilo, procedimiento para su preparacion y su uso como medicamentos | |
| AR085987A1 (es) | Compuestos tri- y tetraciclicos pirazol[3,4-b]piridina como agentes antineoplasicos | |
| AR076435A1 (es) | Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos | |
| AR087273A1 (es) | 3-(fluorovinil)pirazoles y su uso | |
| AR078797A1 (es) | Inhibidores de la caseina quinasa, composiciones farmaceuticas y sus usos para tratar trastornos del snc | |
| MX2018005239A (es) | Derivados de 2-fenil-3,4-dihidropirrolo[2,1-f][1,2,4]triazinona como inhibidores de fosfodiesterasa y sus usos. | |
| PE20141352A1 (es) | Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento | |
| AR076563A1 (es) | Derivados de ciclopenta[c]pirrol-2-carboxilatos, su preparacion y su apli-cacion en terapeutica | |
| DOP2007000022A (es) | Derivados de n-heteroaril-carboxamidas tricíclicas que contienen un resto bencimidazol, su preparación y su aplicación en terapéutica | |
| AR061923A1 (es) | Compuestos derivados de benzofuran-piperidina | |
| PE20121087A1 (es) | Compuestos antiproliferativos, conjugados de los mismos, procedimientos para estos, y usos de los mismos | |
| AR045761A1 (es) | Derivados de 2-piridona como inhibidores de elastasa de neutrofilos | |
| PE20141726A1 (es) | Heterociclilaminas como inhibidores de pi 3k | |
| AR037754A1 (es) | Herbicidas | |
| AR069796A1 (es) | Derivados de bencimidazol, sustituido por carboxilo o por hidroxilo, proceso para prepararlos y composiciones farmaceuticas que los contienen | |
| AR060875A1 (es) | Derivados de 2-piridona como inhibidores de la neutrofilo elastasa humana | |
| AR064889A1 (es) | Derivados de piridopirimidinas, un metodo para su preparacion, una composicion y un producto farmaceutico que los comprenden y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por pde-4 | |
| AR070648A1 (es) | Derivados de bencimidazol sustituido | |
| CO6351734A2 (es) | Compuestos de amida utiles en terapia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |